Navigation Links
Grifols Signs Cooperative Agreement for Commercialization of Immunohematology Diagnostic Products in the US
Date:2/22/2011

BARCELONA, Spain, Feb. 22, 2011 /PRNewswire/ -- Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain has entered into a long-term cooperative agreement with the diagnostics business of Novartis for the commercialization of select Grifols' diagnostic products in the US.  Under the terms of the agreement, Novartis will market and distribute Grifols' immunohematology instruments, assays and other products following US regulatory approvals.  The agreement also covers semi-automated pre-transfusion diagnostic products made by Grifols subsidiaries as well as Progenika blood group antigen genotyping products currently distributed by Grifols.

"Grifols' seventy year history of advancing blood diagnostics complements the Novartis leadership in blood safety and ongoing mission to advance preventive screening," said Oriol Dunach, the head of Diagnostic Grifols.  "Our commercialization agreement with Novartis will serve to enhance transfusion safety throughout the US by providing laboratories with the latest technologies and highest quality services," continued Dunach.  

Novartis is a trusted name in transfusion medicine that will help strengthen Grifols' position in the US blood transfusion market.  Novartis Diagnostics' highly sensitive tests and fully automated nucleic acid testing platforms, developed in partnership with Gen-Probe, are used to test millions of blood donations around the world each year for HIV, Hepatitis, and West Nile Virus.  Today, more than eighty percent of the US blood supply is tested on Novartis systems.  The commercialization agreement with Grifols will add immunohematology instruments to the portfolio of products Novartis Diagnostics can make available to blood banks and hospital transfusion centers.

This agreement leverages an earlier Grifols' distribution agreement with Spanish biotechnology company Progenika Biopharma for its microchip blood typing technology BLOODCHIP®.  Although the use of molecular biology tests in transfusion compatibility testing is still at its early stages, its use is expected to become more widespread as a result of hemovigilance and transfusion safety plans being introduced in many countries.

The agreement comes on the heels of the completion of a new Medion Grifols production facility in Switzerland that makes reagents for the rapid identification of blood groups.  It also follows a threefold production capacity increase for Grifols' immunohematology gel cards in 2009 at its Barcelona facility.  All of Grifols' diagnostic production facilities in Spain are ISO 13485 certified and meet leading industry standards for quality.  

About Grifols

Grifols is a Spanish holding company, specializing in the hospital-pharmaceutical sector, and with a presence in over 90 countries. Since May 2006 it has been listed on the Spanish Continuous Market, and since 2008 it has been included in the Ibex-35. It focuses on the research, development, manufacture and marketing of plasma products, diagnostic systems, intravenous therapies, enteral nutrition and medical supplies. In recent years Grifols has made significant investments in the area of transfusion medicine to ensure the strategic and technological position of the company in this area.


'/>"/>
SOURCE Grifols, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Health Robotics CytoCare(TM) Global Expansion Continues With Grifols International in Latin America
2. AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
3. Grifols Agrees to Acquire Intellectual Property for Treatment of Post-Polio Syndrome From Pharmalink AB
4. Health Robotics CytoCare Continues European Expansion With Grifols and Vall dHebron University Hospital
5. NASDAQ Removes TLCR From Biotechnology Index Pending FTC Decision on Grifols Acquisition
6. Grifols Starts Construction of a New Plasma Fractionation Plant in Barcelona (Parets Del Valles)
7. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
8. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
9. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
10. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
11. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- Story Highlights: , ... health care industry is causing providers to review operating ... offers a suite of solutions for health care providers ... optimization: labor resource analysis, revenue cycle optimization and physician ... and better economics ...
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
Breaking Medicine News(10 mins):